A targeted GLP-1-GIP-lanifibranor conjugate provided broad metabolic benefits in obese mice, indicating a potential new generation of multi-pathway therapies for obesity and type 2 diabetes.
Study: GLP-1R-GIPR-PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice. Image credit: zimmytws / Shutterstock
A recent study published in the journal Nature describes the creation of a novel single-molecule quintuple agonist designed to integrate incretin-mediated metabolic regulation with the anti-inflammatory effects and insulin-sensitizing properties of lanifibranor.
In preclinical models, the compound demonstrated greater efficacy than semaglutide and glucagon-like peptide-1 receptor (GLP-1R) – glucose-dependent insulinotropic polypeptide receptor (GIPR) dual treatment, resulting in marked reductions in body weight, food intake, and blood glucose in obese mice when the drug is administered at a targeted low dose.
Findings support multi-pathway targeted pharmacological strategies for common cardiometabolic diseases such as diabetes and obesity, but preclinical evidence remains limited.
Background of incretin and PPAR agonist therapy
The treatment landscape for obesity and its metabolic complications has rapidly advanced with incretin-based therapies and nuclear receptor modulators. GLP-1R–GIPR agonists such as tirzepatide have shown strong efficacy in reducing body weight, improving glycemic control and even benefiting liver outcomes in steatohepatitis associated with metabolic dysfunction (PULP).
In parallel, peroxisome proliferator-activated receptor (PPAR) fighters, including triple PPARThe α/γ/δ compound lanifibranor, currently in late-stage clinical development, has attracted interest for its metabolic and anti-inflammatory effects. However, incretin therapies may not completely resolve insulin resistance and inflammation, whereas PPAR Agonists may have varied safety profiles, including weight changes and fluid imbalance, highlighting the need for new treatment strategies.
Design and Methods of the Quadruple Athlete Study
To improve metabolic efficiency, this study developed and evaluated a single-molecule quintuple agonist that links incretin-based signaling to peroxisome proliferator-activated receptor (PPAR) activity. Lanifibranor, a triple PPAR agonist targeting α, γ, and δ subtypes, was chemically coupled to a dipeptidyl peptidase-4 (DPP4)-protected incretin agonist backbone (MAR709). This design allowed selective uptake into expressing cells GLP-1 and GIP receptors.
The team randomly assigned mice to treatment groups, ensuring matching for genotype, age, body mass and overall body composition. Animals received subcutaneous injections (5.0 μL/g) of vehicle, semaglutide and GLP-1 in combination with lanifibranor, GIPor both, in defined molar doses. In key efficacy experiments, researchers treated diet-induced obese (DIO) mice for up to 12 days, including regimens for GLP-1–GIP–lanifibranor at doses of 5–50 nmol/kg.
The researchers assessed metabolic outcomes using indirect calorimetry, body composition analysis, and a series of tolerance tests, including glucose, insulin, and pyruvate tolerance tests in fasted mice. They also performed hyperinsulinemic-euglycemic clamp studies and tissue-specific glucose uptake assays to quantify insulin sensitivity and glucose handling. They measured serum metabolites and hormones using enzyme-linked immunosorbent assays (ELISA).
At the molecular level, the group performed massive ribonucleic acid sequencing (bulk RNA-seq) and analyzed differential gene expression. They supplemented these studies with in vitro experiments in human fetal kidney 293T (HEK293T) cells, including bioluminescence resonance energy transfer (BRETT) analyzes and quantification of PPAR– responsive gene activity. Proteomic, immunofluorescence, and conditioned taste aversion assays further characterized the systemic and cellular effects of the drug. All in vivo metabolic assessments were performed by blinded investigators.
Metabolic Effects of GLP-1–GIP–Lanifibranor
In vitrothe GLP-1–GIP-The lanifibranor conjugate showed comparable incretin receptor activity and similar glucose-induced insulin secretion with GLP-1R–GIPR dual receptor backbone. It also caused his expression PPAR-On target genes to a similar extent as lanifibranor, but only in cells expressing incretin receptors, confirming receptor-dependent activity. This targeted delivery strategy enabled pharmacological activity at lanifibranor exposures approximately 6,900-fold below a dose of 30 mg/kg previously required to enhance hepatic metabolism in preclinical settings.
In vivothe single molecule conjugate showed superior efficacy compared to the combined one GLP-1R and GIPR activation, semaglutide, and comparator regimens in both diet-induced and genetic obesity models, suggesting enhanced metabolic control. At 50 nmol/kg daily, GLP-1–GIP–Lanifibranor caused placebo-corrected weight loss 2.63 times greater than GLP-1–lanifibranor after 14 days. Subsequent experiments identified 10 nmol/kg as the primary dose for further testing. These effects were accompanied by marked reductions in fat mass, food intake, and blood glucose, along with improved oral glucose tolerance, increased insulin sensitivity, and stronger suppression of endogenous glucose production, possibly due to reduced hepatic gluconeogenesis and systemic inflammatory activity.
Mechanistically, the treatment improved insulin sensitivity and glucose uptake, particularly in brown adipose tissue, with glucose uptake similar to that of GLP-1–GIP in several other metabolic tissues, without increasing energy expenditure or promoting adipocyte differentiation. Transcriptional profiling identified more than 5,400 differentially expressed genes in liver and over 8,000 in adipose tissue, indicating extensive remodeling of inflammatory and metabolic pathways.
Genetic or pharmacological blockade of it GIP, GLP-1or PPARδ signals significantly reduced metabolic effects, supporting a combined incretin-PPAR mechanism of action. Consistently, mice lacking both incretin receptors showed a complete loss of activity, confirming the requirement for dual receptor involvement.
Preclinical Implications for Obesity and Diabetes
The study highlights the promise of combining incretin biology with nuclear receptor signaling for more comprehensive metabolic control. In preclinical models, the GLP-1–GIP-The lanifibranor conjugate improved weight, glycemia, and indices of glucose, liver, and cardiovascular function in mice using an equivalent dose of lanifibranor approximately 6,900-fold lower than a preclinical dose of 30 mg/kg previously required to improve hepatic metabolism, indicating an improvement in the efficiency of hepatic metabolism. If translated to humans, such multitargeted strategies could better address the growing global burden of obesity and type 2 diabetes, although clinical validation, human safety testing, and mechanistic clarity remain necessary.
New @Nature
A quintuple [GLP-1 + 4 other] receptor agonist drug that overcomes the effects of the dual receptor (GLP-1 and GIP, tirzepatide) in the experimental model against diabetes and obesity
(in case you thought a dual receptor was maximally effective, as seen with retatrutide, a triple… pic.twitter.com/bvjCbj5Y6P– Eric Topol (@EricTopol) April 29, 2026
